AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19018483 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin in combination with albumin
Number of subjects: 0
Study 19018483 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin and albumin
Number of subjects: 0
Study 15671799 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine and Stavudine (ddI+d4T)
Number of subjects: 96
Study 15671799 — intervention group
Group type: COMPARATOR
Intervention: Abacavir and Lamivudine (ABC+3TC)
Number of subjects: 96
Study 15671799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 96
Study 12552210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + 1 microg neostigmine
Number of subjects: 60
Study 12552210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + 2.5 microg neostigmine
Number of subjects: 60
Study 12552210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + 5 microg neostigmine
Number of subjects: 60
Study 12552210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 microg)
Number of subjects: 60
Study 12552210 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60
Study 10550412 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 0
Study 8681637 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (lipopolysaccharide) inhalation
Number of subjects: 14
Study 8681637 — intervention group
Group type: EXPERIMENTAL
Intervention: CDE (corn dust extract) inhalation
Number of subjects: 14
Study 8681637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-endotoxin LPS and CDE exposures
Number of subjects: 14
Study 8681637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-endotoxin LPS and CDE exposures
Number of subjects: 14
Study 1869725 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone
Number of subjects: 510
Study 6857251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 0
Study 6857251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 6857251 — intervention group
Group type: COMPARATOR
Intervention: Control animals (dissociated drug histories)
Number of subjects: 0
Study 29578381 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased stride length
Number of subjects: 19
Study 29578381 — intervention group
Group type: COMPARATOR
Intervention: Shorter stride length
Number of subjects: 19
Study 29578381 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer stride length
Number of subjects: 19
Study 29578381 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer strides
Number of subjects: 19
Study 29463612 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI
Number of subjects: 302
Study 29463612 — intervention group
Group type: COMPARATOR
Intervention: CTO-No PCI
Number of subjects: 302
Study 27014997 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (IV 10 mg/kg at weeks 0, 2, 4 followed by subcutaneous 150 mg or 75 mg)
Number of subjects: 606
Study 27014997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 27014997 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (IV→150 mg)
Number of subjects: 606
Study 27014997 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (IV→75 mg)
Number of subjects: 606
Study 24613784 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 82
Study 24613784 — intervention group
Group type: EXPERIMENTAL
Intervention: LC patients
Number of subjects: 82
Study 24613784 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis (LC)
Number of subjects: 82
Study 24613784 — intervention group
Group type: COMPARATOR
Intervention: Functional status
Number of subjects: 82
Study 23281381 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional catheterization + bedside fluoroscopy
Number of subjects: 168
Study 23281381 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheterization
Number of subjects: 168
Study 20204511 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator intervention
Number of subjects: 100
Study 20204511 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 100
Study 18629732 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention consisting of education and psychological support, with or without pharmacological therapy, associated with follow-up phone calls
Number of subjects: 196
Study 18629732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 196
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization performed in trials
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking in medical treatments
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of basal characteristics
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient losses during follow-up
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of P values
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Measure of effect reported
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials performed in the US
Number of subjects: 226
Study 15870599 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of statistician or epidemiologist
Number of subjects: 226
Study 11796083 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified biscuit (beta-carotene, iron, and iodine)
Number of subjects: 108
Study 9704197 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaltoprofen
Number of subjects: 46
Study 8310980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized group
Number of subjects: 311
Study 2647846 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg once daily)
Number of subjects: 8
Study 2647846 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of treatment
Number of subjects: 8
Study 1091665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 40
Study 1091665 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 40
Study 1091665 — intervention group
Group type: COMPARATOR
Intervention: Previous medication
Number of subjects: 40
Study 29927290 — intervention group
Group type: EXPERIMENTAL
Intervention: Family based reintegration program aimed at enhancing reflective functioning
Number of subjects: 0
Study 29927290 — intervention group
Group type: COMPARATOR
Intervention: Baseline relationship satisfaction
Number of subjects: 0
Study 29927290 — intervention group
Group type: COMPARATOR
Intervention: Couple distress
Number of subjects: 0
Study 28241386 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder
Number of subjects: 178
Study 28241386 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 178
Study 26710315 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 0
Study 26710315 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (placebo)
Number of subjects: 0
Study 25081673 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS) group
Number of subjects: 60
Study 25081673 — intervention group
Group type: COMPARATOR
Intervention: Class group
Number of subjects: 60
Study 22648444 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level light therapy (LLLT)
Number of subjects: 31
Study 22648444 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 31
Study 19431196 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of promoter hypermethylation of p16 gene
Number of subjects: 38
Study 19431196 — intervention group
Group type: COMPARATOR
Intervention: Histologically free margins
Number of subjects: 38
Study 19431196 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive molecular margins
Number of subjects: 38
Study 17692110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutropin alfa 75 IU and follitropin alfa (75-225 IU)
Number of subjects: 31
Study 15039504 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 26
Study 15039504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12739312 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans (acute migraine pharmacotherapy)
Number of subjects: 0
Study 12739312 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive therapy
Number of subjects: 0
Study 12739312 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health initiatives
Number of subjects: 0
Study 9287046 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (50 microg/kg b.i.d.)
Number of subjects: 8
Study 9287046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8281563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride solution (0.5% F) applied 10 times a year
Number of subjects: 199
Study 8281563 — intervention group
Group type: COMPARATOR
Intervention: Standard topical amine fluoride solution (1% F)
Number of subjects: 199
Study 2883491 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-urea breath test
Number of subjects: 26
Study 2883491 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic biopsy
Number of subjects: 26
Study 30618475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-4.5 mg/day)
Number of subjects: 530
Study 30618475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 26499921 — intervention group
Group type: EXPERIMENTAL
Intervention: E10030 (0.03 mg) in combination with ranibizumab (0.5 mg)
Number of subjects: 23
Study 26499921 — intervention group
Group type: EXPERIMENTAL
Intervention: E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg)
Number of subjects: 23
Study 24860156 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen during and for 2 h after surgery
Number of subjects: 1386
Study 24860156 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen during and for 2 h after surgery
Number of subjects: 1386
Study 24860156 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1386
Study 24860156 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1386
Study 24860156 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized disease
Number of subjects: 1386
Study 22900702 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (400 mg, equivalent to 2 cups of coffee)
Number of subjects: 23
Study 22900702 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study 20425165 — intervention group
Group type: EXPERIMENTAL
Intervention: CorCap Cardiac Support Device (Acorn Cardiovascular, St. Paul, MN)
Number of subjects: 0
Study 20425165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery insights
Number of subjects: 0
Study 17693101 — intervention group
Group type: EXPERIMENTAL
Intervention: Inserted insole without shoes
Number of subjects: 207
Study 17693101 — intervention group
Group type: EXPERIMENTAL
Intervention: Strapped insole with shoes
Number of subjects: 207
Study 17693101 — intervention group
Group type: EXPERIMENTAL
Intervention: Strapped insole without shoes
Number of subjects: 207
Study 17693101 — intervention group
Group type: COMPARATOR
Intervention: Placebo with shoes
Number of subjects: 207
Study 17693101 — intervention group
Group type: COMPARATOR
Intervention: Inserted insole with shoes
Number of subjects: 207
Study 17064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao 500 mg three times daily for 5 days
Number of subjects: 197
Study 17064525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 17064525 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Number of subjects: 197
Study 14655910 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 788
Study 14655910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study 10640625 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser stimulation of the dorsum of the left hand
Number of subjects: 12
Study 10640625 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation of the left median nerve at wrist
Number of subjects: 12
Study 10640625 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct recording of somatosensory evoked potentials (SEPs) from peri‐Rolandic cortex
Number of subjects: 12
Study 8667142 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap with osseous resection surgery (FO)
Number of subjects: 82
Study 8667142 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman surgery (MW)
Number of subjects: 82
Study 8667142 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing (RP)
Number of subjects: 82
Study 8667142 — intervention group
Group type: COMPARATOR
Intervention: Coronal scaling (CS)
Number of subjects: 82
Study 8213620 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated split-course radiotherapy (300 cGy x 10, 3 weeks rest, 300 cGy x 10)
Number of subjects: 137
Study 8213620 — intervention group
Group type: COMPARATOR
Intervention: Continuous radiotherapy (200‐220 cGy up to 6000‐6600 cGy)
Number of subjects: 137
Study 8213620 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated split-course radiotherapy
Number of subjects: 137
Study 8213620 — intervention group
Group type: COMPARATOR
Intervention: Continuous radiotherapy
Number of subjects: 137
Study 3799505 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of elemental calcium for 8 weeks
Number of subjects: 70
Study 3799505 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation in mildly hyperlipidemic normotensive subjects
Number of subjects: 70
Study 3799505 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 70
Study 31514854 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-IR spectroscopy
Number of subjects: 900
Study 31514854 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-NIR spectroscopy
Number of subjects: 900
Study 31514854 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR-MIR spectroscopy
Number of subjects: 900
Study 29426006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic treatment (multi-modal)
Number of subjects: 151
Study 29426006 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (multi-modal)
Number of subjects: 151
Study 27884120 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA filter (Filtryzer BK‐F)
Number of subjects: 20
Study 27884120 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR17 filter
Number of subjects: 20
Study 27884120 — intervention group
Group type: COMPARATOR
Intervention: F7 filter
Number of subjects: 20
Study 27884120 — intervention group
Group type: EXPERIMENTAL
Intervention: All filters
Number of subjects: 20
Study 24857271 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad-based image guidance system
Number of subjects: 5
Study 24857271 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional mouse interface
Number of subjects: 5
Study 22834721 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and support from a chosen close female relative from admission until 2 hours after birth
Number of subjects: 120
Study 22834721 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 120
Study 19196894 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC algorithm
Number of subjects: 120
Study 19196894 — intervention group
Group type: COMPARATOR
Intervention: Matias protocol
Number of subjects: 120
Study 19196894 — intervention group
Group type: COMPARATOR
Intervention: Bath protocol
Number of subjects: 120
Study 17765316 — intervention group
Group type: EXPERIMENTAL
Intervention: p38-MAPK inhibitors
Number of subjects: 0
Study 14999030 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based progressive strength, balance, and general physical activity intervention
Number of subjects: 72
Study 14999030 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (home-based nutrition education)
Number of subjects: 72
Study 12052577 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine (pharmaceutical heroin)
Number of subjects: 0
Study 12052577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) application of heroin under medical supervision
Number of subjects: 0
Study 9621802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutridrink (early enteral nutrition)
Number of subjects: 60
Study 9621802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 7938560 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 0
Study 7938560 — intervention group
Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 0
Study 7938560 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 3356050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 50 mg
Number of subjects: 46
Study 3356050 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 46
Study 29055882 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to NAS advertisements
Number of subjects: 1128
Study 29055882 — intervention group
Group type: COMPARATOR
Intervention: No-message control group
Number of subjects: 1128
Study 27146725 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND)
Number of subjects: 145
Study 27146725 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 145
Study 25898367 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cognitive training
Number of subjects: 85
Study 25898367 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted cognitive training
Number of subjects: 85
Study 25898367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 85
Study 23639047 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO > 20 ppb in non-asthmatics
Number of subjects: 1119
Study 23639047 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO > 20 ppb in asthmatics
Number of subjects: 1119
Study 23639047 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO as a predictor of atopy
Number of subjects: 1119
Study 23639047 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO in non-asthmatics
Number of subjects: 1119
Study 23639047 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO in asthmatics
Number of subjects: 1119
Study 19948873 — intervention group
Group type: EXPERIMENTAL
Intervention: TSC 30%
Number of subjects: 6
Study 19948873 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 6
Study 18230250 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination drugs (FDCs)
Number of subjects: 0
Study 18230250 — intervention group
Group type: COMPARATOR
Intervention: Loose drugs
Number of subjects: 0
Study 16340598 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 159
Study 16340598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 12884988 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation with 8% sevoflurane and nitrous oxide
Number of subjects: 60
Study 12884988 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway insertion with 8% sevoflurane and nitrous oxide
Number of subjects: 60
Study 11126178 — intervention group
Group type: COMPARATOR
Intervention: Serum concentration of carboxyterminal propeptyde of procollagen type I (P I CP)
Number of subjects: 25
Study 11126178 — intervention group
Group type: COMPARATOR
Intervention: Serum concentration of aminoterminal propeptyde of procollagen type III (P III NP)
Number of subjects: 25
Study 11126178 — intervention group
Group type: COMPARATOR
Intervention: Serum concentration of carboxyterminal telopeptyde of collagen type I (I CTP)
Number of subjects: 25
Study 8648207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 0
Study 8648207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 0
Study 8648207 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study 1346562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 0.4 mg
Number of subjects: 0
Study 1346562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 0.8 mg
Number of subjects: 0
Study 1346562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 1.2 mg
Number of subjects: 0
Study 6437131 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl
Number of subjects: 22
Study 6437131 — intervention group
Group type: COMPARATOR
Intervention: Tocainide HCl (900 mg daily)
Number of subjects: 22
Study 30621783 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-CSAM
Number of subjects: 0
Study 30621783 — intervention group
Group type: COMPARATOR
Intervention: SMASH, MyoVision, MuscleJ
Number of subjects: 0
Study 30594169 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching in the luteal phase of the natural cycle
Number of subjects: 792
Study 30594169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endometrial scratching)
Number of subjects: 792
Study 27456602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-step incision
Number of subjects: 58
Study 27456602 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted V incision
Number of subjects: 58
Study 24488498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose enteric-coated aspirin tablets (100 mg/day for 2 years)
Number of subjects: 311
Study 24488498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 22994910 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and child health nurse (MCHN) IPV screening intervention
Number of subjects: 8
Study 22994910 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Abuse Scale for measuring IPV
Number of subjects: 8
Study 22994910 — intervention group
Group type: EXPERIMENTAL
Intervention: Process and impact evaluation data (online surveys and key stakeholders interviews)
Number of subjects: 8